MacroGenics (MGNX) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed MacroGenics (MGNX) over the past year, gaining 157.4% versus a gain of 113.7%. Over five years, MGNX leads with a -81.1% price change compared with -92.5% for QTTB. Q32 Bio is the larger company by market cap ($248.3 million vs $238.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | QTTB |
|---|---|---|
| Share price | $3.74 | $8.34 |
| Market cap | $238.24M | $248.28M |
| 1-day change | +5.35% | +3.09% |
| YTD return | +132.30% | +151.20% |
| 1-year return | +113.71% | +157.41% |
| 5-year return | -81.05% | -92.53% |
| P/E ratio (TTM) | — | 2.65 |
| EPS (TTM) | $-1.70 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $23.57 |
| 52-week low | $1.29 | $1.91 |
| Distance from 52-week high | -26.38% | -64.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +113.90% | +374.82% |
| Average volume | 622.92K | 1.38M |
| Shares outstanding | 63.70M | 29.77M |
| Employees | 293 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed MGNX by 43.7 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
MGNX vs QTTB FAQ
Which is bigger, MacroGenics or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $248.28M compared with $238.24M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or QTTB?
QTTB returned +157.41% over the past 12 months, compared with +113.71% for MGNX (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.